Vendor Intelligence Report: Hebei Rimao Technology

Published 3 Jul 2026. 22-page investigative report on who is behind Hebei Rimao Technology: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 52 Finnrick lab tests, Hebei Rimao Technology records 38 pass / 14 fail — an overall pass rate of 73%. The catalog is uneven rather than uniformly bad. GHK-Cu is the cleanest small-sample signal and Retatrutide has the stronger broader record, while Tirzepatide is materially weaker and includes severe underfill plus a no-active field note. BPC-157 also sits in the poor-choice zone, and ratings compress under stricter purity and fill scoring.

The vendor-level record is more concerning than the best product scores. The public footprint supports a short 2025 peptide identity: one archived peptide-site capture, a dormant GLP-1 Forum sales thread, and an expired hbrimao.com domain now in redemption. The sister Rimao domain was non-resolving and near expiry, leaving buyers without a stable canonical channel.

Corporate evidence points to a dual-channel exporter. The active Made-in-China profile is a Gold Member and Audited Supplier for toys and baby walkers, and a shared John contact bridges that profile to the archived peptide site. That badge is supplier verification, not peptide GMP assurance; no pharmaceutical manufacturing audit was found.

The document trail adds another hard verification problem: Krause Analytical certificate links posted by Bella returned 404 on the lab server. The report treats Janoshik IDs and a possible Bella MEIPEPTIDE profile as unresolved leads, not adverse findings. The practical read is product-specific: Hebei Rimao is a more defensible GHK-Cu or Retatrutide candidate than a Tirzepatide or BPC-157 source, but only if channel and COA verification can be independently rebuilt.

Inside the full report:

  • Product-by-methodology Finnrick charts and Appendix A for all five tested products
  • Dated domain timeline covering hbrimao.com redemption status and the rimao.com watch point
  • Made-in-China profile and audit assessment linking the toy-export identity to the peptide channel
  • GLP-1 Forum analysis of Bella, John, contact handles, payment rails, and dormant vendor status
  • COA verification workup for Krause certificate URLs and unresolved Janoshik IDs
  • Risk matrix plus rebrand-monitoring identifiers, including the unverified Bella MEIPEPTIDE lead

Risk assessment

  • Document-fabrication risk — high: Four Krause Analytical COA IDs posted by Bella returned 404 on Krause’s server, indicating fabricated or invalid third-party verification links.
  • Tirzepatide quality-control risk — high: Tirzepatide has a 68.57% Finnrick rating, with field records identifying severe underfills and one no-active sample.
  • BPC-157 and Tesamorelin reliability risk — high: BPC-157 is 49.11% across 6 tests and Tesamorelin is 49.7% across 5 tests, making both poor product-specific choices from this vendor.
  • Corporate/channel obfuscation risk — high: A toy and baby-walker B2B supplier profile is operationally linked to peptide sales, but no pharmaceutical/GMP peptide audit was found.
  • Official-channel disappearance and brand-confusion risk — high: hbrimao.com expired and is in redemption, rimao.com is non-resolving and near expiry, and the GLP-1 vendor account is inactive.
  • Facility and registry-verification risk — medium: The listed address appears consistent with a shared industrial-park setting, while Chinese registry fields such as USCC, shareholders, and registered capital were not retrieved.